ADA: Dulaglutide Tied to Decline in Cardiovascular Events in T2DM
TUESDAY, June 11, 2019 -- Dulaglutide is associated with a reduction in cardiovascular events and renal outcomes among patients with type 2 diabetes, according to two studies published online June 9 in The Lancet to coincide with the annual meeting...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Pharmaceuticals | Study